文献速递脊柱关节炎

依那西普与甲氨蝶呤单药或联合治疗银屑病关节炎试验中复合指标的性能

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究基于一项48周随机对照试验,纳入851例银屑病关节炎患者,比较甲氨蝶呤(MTX)单药、依那西普单药及联合治疗的复合指标反应性。结果显示PASDAS在连续复合指标中最敏感,其变化与主要和关键次要终点一致。

要点

  • PASDAS是所评估的连续复合指标中最敏感者,效应量和标准化反应最大。
  • 除PASDAS外,其余连续复合指标第24周评分变化主要由关节计数变化驱动。
  • PASDAS的变化由医师和患者整体评估驱动。

核心结论

  • PASDAS是所评估的连续复合指标中最敏感者,其结果与方案定义的主要和关键次要结局一致。

研究设计与样本

  • 48周随机对照试验,851例银屑病关节炎患者随机接受每周MTX 20 mg、依那西普50 mg或MTX联合依那西普治疗。

主要发现

  • 第24周,依那西普治疗组达到ACR 20(主要终点)和MDA(关键次要终点)显著优于MTX单药。
  • 第24周较基线的评分变化中,PASDAS在依那西普治疗组相对MTX单药显示较大变化,效应量和标准化反应最大。
  • 除PASDAS外,所有连续复合指标第24周较基线的总体评分变化由关节计数变化驱动。
  • PASDAS的评分变化由医师和患者整体评估驱动。

关键数值与推荐

  • 二分类复合指标包括ACR 20/50/70反应、MDA和VLDA。
  • 连续复合指标包括DAS28-CRP、CDAI、SDAI、DAPSA和PASDAS。
  • 第24周依那西普治疗组达到ACR 20(主要终点)和MDA(关键次要终点)显著优于MTX单药。

临床怎么用

  • 在银屑病关节炎疾病活动度评估中,PASDAS可能更好地量化疾病负担变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine which composite measures are most sensitive to change when measuring psoriatic arthritis (PsA) disease activity, analyses compared the responsiveness of composite measures used in a 48-week randomized, controlled trial of MTX and etanercept in patients with PsA. METHODS: The trial randomised 851 patients to receive weekly: MTX (20 mg/week), etanercept (50 mg/week) or MTX plus etanercept. Dichotomous composite measures examined included ACR 20/50/70 responses, minimal disease activity (MDA) and very low disease activity (VLDA). Continuous composite measures examined included Disease Activity Score (28 joints) using CRP (DAS28-CRP), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), Disease Activity for Psoriatic Arthritis (DAPSA) and Psoriatic Arthritis Disease Activity Score (PASDAS). RESULTS: At week 24, etanercept-treated groups were significantly more effective than MTX monotherapy to achieve ACR 20 (primary end point) and MDA (key secondary end point). When examining score changes from baseline at week 24 across the five continuous composite measures, PASDAS demonstrated relatively greater changes in the etanercept-treated groups compared with MTX monotherapy and had the largest effect size and standardized response. Joint count changes drove overall score changes at week 24 from baseline in all the continuous composite measures except for PASDAS, which was driven by the Physician and Patient Global Assessments. CONCLUSION: PASDAS was the most sensitive continuous composite measure examined with results that mirrored the protocol-defined primary and key secondary outcomes. Composite measures with multiple domains, such as PASDAS, may better quantify change in PsA disease burden. TRAIL REGISTRATION: https://ClinicalTrials.gov, number NCT02376790.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Coates LC, Merola JF, Mease PJ, et al. Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. Rheumatology (Oxford). 2021. PMID: 32864685. doi:10.1093/rheumatology/keaa271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。